Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With TAS-102 (Lonsurf) and Bevacizumab in Refractory Metastatic Colorectal Cancer — Live-RF

Refractory Metastatic Colorectal Cancer Clinical Trial

Official title:
Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With TAS-102 (Lonsurf) and Bevacizumab in Refractory Metastatic Colorectal Cancer

Status Recruiting

Clinical Trial Summary

Combined chemotherapy and radiofrequency electromagnetic field treatment for patients with liver dominant refractory metastatic colorectal cancer

Clinical Trial Description

Charité Universitätsmedizin Berlin is currently the only German University Hospital with an available capacitive radiofrequency electromagnetic field treatment device. While there is only data available regarding the low toxicity profile of radiofrequency electromagnetic field treatment for various regions of the body including the abdomen there is no data available on the combined effect of TAS-102 and Bevacizumab and radiofrequency electromagnetic field treatment. The investigators aim to conduct a feasibility trial and plan to compare the results with data of a prospective trial with a comparable patient population. ;

Study Design

Related Conditions & MeSH terms

Colorectal Neoplasms
Refractory Metastatic Colorectal Cancer

Clinical Trial Details

NCT number	NCT05991102
Study type	Interventional
Source	Charite University, Berlin, Germany
Contact	Pirus Ghadjar, Prof. Dr.
Phone	+49 30 450 527318
Email	pirus.ghadjar@charite.de
Status	Recruiting
Phase	N/A
Start date	December 15, 2023
Completion date	November 2026

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04527068` - QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer	Phase 2
Recruiting	`NCT05248048` - NKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer	Early Phase 1
Completed	`NCT04737187` - Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients	Phase 3
Active, not recruiting	`NCT05205330` - A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients	Phase 1/Phase 2
Active, not recruiting	`NCT05733611` - RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC	Phase 2
Recruiting	`NCT05213195` - NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer	Phase 1
Completed	`NCT02860546` - A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC	Phase 2
Not yet recruiting	`NCT06343116` - Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer	Phase 3